목적 : 전립선암 환자에서 외부 방사선치료의 효과 및 안전성을 평가하고 최적의 방사선치료 방법을 알아보고자 함이 본 연구의 목적이다. 재료 및 방법 : 1987년 9월부터 2000년 3월까지 본원에서 근치적 목적의 외부 방사선치료를 시행한 50명의 환자를 후향적으로 분석하였다. 요도관통 전립선 절제술 및 초음파를 이용한 조직검사를 시행하여 조직학적 진단을 확인하였다. 진단시의 주된 증상은 직장촉진시 전립선의 종괴 촉지, 빈뇨 및 급뇨, 소변시 통증호소 등이었다. 환자 나이의 분포는 51세부터 87세 이었고 중앙값은 63세이었다. A병기 환자는 6명, B병기 환자는 20명, C병기 환자는 26명, D1병기 환자는 8명이었다. 모든 환자는 10 백만볼트 에너지의 선형가속기를 이용하여 치료하였다. 4문대항 골반 상자 치료기법을 사용하여 $45\~50.4\;Gy$를 전골반부위에 조사 후 조사야를 축소하여 총조사량 $66\~70\;Gy$까지 추가조사를 실시하였다. 추적기간은 1년 내지 8년이었다. 결과 : A병기, B병기, C병기 및 D1병기 환자에서 5년 및 7년 실질 생존율은 각각 $100\%$ 및 $84\%,\;83\%$ 및 $72\%,\;67\%$ 및 $54\%,\;40\%$ 및 $30\%$이었다. 각각의 병기에서 5년 및 7년 무병생존율은 $84\%$ 및 $84\%,\;77\%$ 및 $67\%,\;48\%$ 및 $40\%,\;33\%$, 및 $25\%$이었다. B병기 환자에서 조직학적 분화에 따른 5년 무병생존율이 $ 80\%,\;80\%$ 및 $50\%$이었고, C병기 환자에서는 각각 $64\%,\;44\%$ 및 $33\%$이었다. 생존 5년시의 국소 제어율은 A, B, C, D1병기에서 각각 $84\%,\;85\%,\;78\%$ 및 $50\%$이었다. 경증 및 중등도의 합병증은 $22\%$의 환자에서 관찰되었고, 수술적 처치를 요하는 중증의 합병증은 $3\%$의 환자에서만 발생하였다. 결론 : 본 연구는 전립선암 환자에서 근치적 목적의 외부 방사선치료가 효과적이고 안전한 치료 방법임을 확인하였고 국소제어 및 생존율에서 만족할 만한 결과를 나타내었다.
목적 : 전립선암 환자에서 외부 방사선치료의 효과 및 안전성을 평가하고 최적의 방사선치료 방법을 알아보고자 함이 본 연구의 목적이다. 재료 및 방법 : 1987년 9월부터 2000년 3월까지 본원에서 근치적 목적의 외부 방사선치료를 시행한 50명의 환자를 후향적으로 분석하였다. 요도관통 전립선 절제술 및 초음파를 이용한 조직검사를 시행하여 조직학적 진단을 확인하였다. 진단시의 주된 증상은 직장촉진시 전립선의 종괴 촉지, 빈뇨 및 급뇨, 소변시 통증호소 등이었다. 환자 나이의 분포는 51세부터 87세 이었고 중앙값은 63세이었다. A병기 환자는 6명, B병기 환자는 20명, C병기 환자는 26명, D1병기 환자는 8명이었다. 모든 환자는 10 백만볼트 에너지의 선형가속기를 이용하여 치료하였다. 4문대항 골반 상자 치료기법을 사용하여 $45\~50.4\;Gy$를 전골반부위에 조사 후 조사야를 축소하여 총조사량 $66\~70\;Gy$까지 추가조사를 실시하였다. 추적기간은 1년 내지 8년이었다. 결과 : A병기, B병기, C병기 및 D1병기 환자에서 5년 및 7년 실질 생존율은 각각 $100\%$ 및 $84\%,\;83\%$ 및 $72\%,\;67\%$ 및 $54\%,\;40\%$ 및 $30\%$이었다. 각각의 병기에서 5년 및 7년 무병생존율은 $84\%$ 및 $84\%,\;77\%$ 및 $67\%,\;48\%$ 및 $40\%,\;33\%$, 및 $25\%$이었다. B병기 환자에서 조직학적 분화에 따른 5년 무병생존율이 $ 80\%,\;80\%$ 및 $50\%$이었고, C병기 환자에서는 각각 $64\%,\;44\%$ 및 $33\%$이었다. 생존 5년시의 국소 제어율은 A, B, C, D1병기에서 각각 $84\%,\;85\%,\;78\%$ 및 $50\%$이었다. 경증 및 중등도의 합병증은 $22\%$의 환자에서 관찰되었고, 수술적 처치를 요하는 중증의 합병증은 $3\%$의 환자에서만 발생하였다. 결론 : 본 연구는 전립선암 환자에서 근치적 목적의 외부 방사선치료가 효과적이고 안전한 치료 방법임을 확인하였고 국소제어 및 생존율에서 만족할 만한 결과를 나타내었다.
Purpose : To evaluate effect and tolerance of external beam radiotherapy for carcinoma of the prostate and define the optimal radiotherapeutic regimen. Materials and methods : We retrospectively analyzed the records of 60 patients with prostate cancer who were treated with external beam radiotherapy...
Purpose : To evaluate effect and tolerance of external beam radiotherapy for carcinoma of the prostate and define the optimal radiotherapeutic regimen. Materials and methods : We retrospectively analyzed the records of 60 patients with prostate cancer who were treated with external beam radiotherapy with curative intent in our institution between September, 1987 and March, 2000. Histologic diagnosis was established by transurethral resection or ultrasonography guided biopsy. The major presenting symptoms were a nodule at routine prostatic examination and frequency and urgency of urination, along with dysuria. The median age was 63 years with range of 51 to 87 years. There were 6 patients in Stage A, 20 in Stage 8, 26 in Stage C, and 8 in Stage Dl. All patients were treated with megavoltage equipment producing 10 MV photons. The 4 field pelvic brick technique was used to a dose of 45 Gy or 50.4 Gy at 1.8 Gy per day in 5 to 6 weeks, after which a small boost field was delivered 2.0 Gy per day to a total dose of 66 to 70 Gy. The follow-up period ranged from 1 to 8 years. Results : Actuarial 5-year and 7-year survival rates for Stage A, B, C, and D1 were $100\%\;and\;84\%$, $83\%\;and\;72\%$, $67\%\;and\;54\%$, and $v$, respectively. The corresponding 5-year and 7-year relapse free survival rates were $84\%\;and\;84\%$, $77\%\;and\;67\%$, $48\%\;and\;40\%$, and $33\%\;and\;25\%$, respectively. Relapse free 5-year survival rates for Stage B were $80\%,\;80\%,\;and\;50\%$ for well, moderately, and poorly differentiated tumors, respectively. These were $64\%,\;44\%,\;and\;33\%$ for Stage C, respectively. The local control rates at 5 years were $84\%,\;85\%,\;78\%,\;and\;60\%$ for Stage A, B, C, and D1, respectively. Mild to moderate complications were observed in $22\%$ of patients. Severe complications requiring surgical procedures were documented in only $3\%$ of patients. Conclusion : This study confirms that external beam irradiation is an effective and safe treatment for prostatic cancer, providing long-term local control and good survival with acceptable complications.
Purpose : To evaluate effect and tolerance of external beam radiotherapy for carcinoma of the prostate and define the optimal radiotherapeutic regimen. Materials and methods : We retrospectively analyzed the records of 60 patients with prostate cancer who were treated with external beam radiotherapy with curative intent in our institution between September, 1987 and March, 2000. Histologic diagnosis was established by transurethral resection or ultrasonography guided biopsy. The major presenting symptoms were a nodule at routine prostatic examination and frequency and urgency of urination, along with dysuria. The median age was 63 years with range of 51 to 87 years. There were 6 patients in Stage A, 20 in Stage 8, 26 in Stage C, and 8 in Stage Dl. All patients were treated with megavoltage equipment producing 10 MV photons. The 4 field pelvic brick technique was used to a dose of 45 Gy or 50.4 Gy at 1.8 Gy per day in 5 to 6 weeks, after which a small boost field was delivered 2.0 Gy per day to a total dose of 66 to 70 Gy. The follow-up period ranged from 1 to 8 years. Results : Actuarial 5-year and 7-year survival rates for Stage A, B, C, and D1 were $100\%\;and\;84\%$, $83\%\;and\;72\%$, $67\%\;and\;54\%$, and $v$, respectively. The corresponding 5-year and 7-year relapse free survival rates were $84\%\;and\;84\%$, $77\%\;and\;67\%$, $48\%\;and\;40\%$, and $33\%\;and\;25\%$, respectively. Relapse free 5-year survival rates for Stage B were $80\%,\;80\%,\;and\;50\%$ for well, moderately, and poorly differentiated tumors, respectively. These were $64\%,\;44\%,\;and\;33\%$ for Stage C, respectively. The local control rates at 5 years were $84\%,\;85\%,\;78\%,\;and\;60\%$ for Stage A, B, C, and D1, respectively. Mild to moderate complications were observed in $22\%$ of patients. Severe complications requiring surgical procedures were documented in only $3\%$ of patients. Conclusion : This study confirms that external beam irradiation is an effective and safe treatment for prostatic cancer, providing long-term local control and good survival with acceptable complications.
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
제안 방법
Patients were seen at 1 month and 3 months after irradiation, and at 3 month to 4 month intervals thereafter by us or their referring physicians. Histoiy and careful examination of the prostate were carried out for evaluation of tumor control.
대상 데이터
Clinical stage and histologic differentiation are shown in Table 2. There were 6 patients in Stage A, 20 in Stage B, 26 in Stage C, and 8 in Stage DI. The percent distribution for well-differentiated, moderately differentiated, and poorly differentiated was 67, 16, and 16 for Stage A, 45, 45, and 10 for Stage B, and 31, 35, and 35 for Stage C disease.
성능/효과
Actuarial 5-year and 7-year survival rates for Stage A, B, C, and DI disease were 100%, 84%, 83% and 72%, 67% and 54%, and 40% and 30%, respectively. The corresponding 5-year and 7-year relapse free survival rates were 84% and 84%, 77% and 67%, 48% and 40%, and 33% and 25%, respectively.
The relapse pattern for each stage is shown in Table 3. Among the patients who failed, 57% showed foilure with disseminated disease only, 14% with metastatic foci and local recurrence, and 29% with local recurrence only.
The 5-year, 10-year, and 15-year survival rates were 81%, 60%, and 35%, for disease limited to the prostate, respectively. The corresponding survival rates for patients with ex- tracapsular exteision were 61%, 36%, and 18%, respectively.
54%, and 40% and 30%, respectively. The corresponding 5-year and 7-year relapse free survival rates were 84% and 84%, 77% and 67%, 48% and 40%, and 33% and 25%, respectively. Relapse free 5-year survival rates for Stage B disease were 80%, 80%, and 50% for well, moderately, and poorly differentiated tumors, respectively.
This report confirms that external beam irradiation is an effective and safe treatment for prostate cancer, providing long-term local control and good survival with acceptable complications.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.